Diclofenac etalhyaluronate

Diclofenac etalhyaluronate (INN, USAN; trade name Joycle) is an anti-inflammatory and joint function improving drug. In Japan it is approved for use in the treatment of knee osteoarthritis.[1][2]

Diclofenac etalhyaluronate
Clinical data
Trade namesJoycle
Other namesDiclofenac etalhyaluronate sodium (JAN); SI-613
Legal status
Legal status
  • Rx-only in Japan
Identifiers
PubChem SID
UNII
KEGG

Chemically, diclofenac etalhyaluronate consists of the drug diclofenac, a nonsteroidal antiinflammatory drug, covalently linked to hyaluronic acid.[3][4] In the body, diclofenac is slowly cleaved and released, allowing diclofenac etalhyaluronate to function as a sustained-release form of diclofenac.

References

edit
  1. ^ "Diclofenac etalhyaluronate - Seikagku Corporation". Adis Insight. Springer Nature Switzerland AG.
  2. ^ "New Drug Approvals in Japan". KEGG.
  3. ^ Kisukeda T, Onaya J, Yoshioka K (2019). "Effect of diclofenac etalhyaluronate (SI-613) on the production of high molecular weight sodium hyaluronate in human synoviocytes". BMC Musculoskelet Disord. 20 (201): 201. doi:10.1186/s12891-019-2586-0. PMC 6511136. PMID 31077160.
  4. ^ Nishida Y, Kano K, Nobuoka Y, Seo T (September 2021). "Efficacy and Safety of Diclofenac-Hyaluronate Conjugate (Diclofenac Etalhyaluronate) for Knee Osteoarthritis: A Randomized Phase III Trial in Japan". Arthritis & Rheumatology. 73 (9). Hoboken, N.J.: 1646–1655. doi:10.1002/art.41725. PMC 8456865. PMID 33749997.